Acculturation strategies and blood cortisol in colombian Migrants in Chile.

BACKGROUND: migration is a worldwide phenomenon that is growing at an accelerated pace. When people who migrate come into contact with a new culture, they are immersed in a process called acculturation. In this process, people oscillate between maintaining their own culture or acquiring the culture and customs of the host country, resulting in the so-called acculturation strategies. According to Berry's proposal, there are four main acculturation strategies: assimilation, integration, marginalization and separation. The few existing studies of Latinos in an Anglo-Saxon country relate the use of the integration strategy (biculturalism) with lower cortisol levels. No studies have been found on the subject in Latino migrants in a Latino country. METHOD: a cross-sectional design was used to analyze the relationship between acculturation strategies and blood cortisol levels, based on the hypothesis that an integration strategy or biculturalism would be linked to lower cortisol levels. The study involved 314 Colombian migrants in Chile, who were evaluated with a scale of acculturation strategies according to the model proposed by Berry, in addition to providing blood samples to analyze cortisol levels. RESULTS: migrants who show a preference for leave behind the culture of the country of origin have higher levels of cortisol ng/ml in blood. According to multiple comparisons the mean cortisol value was significantly different between integrated and assimilated subjects, with the mean cortisol of the integrated being significantly lower than that of the subjects typed as marginalized. CONCLUSION: The patterns of the relationship between biculturalism and cortisol found in Latino migrants in Anglo-Saxon countries are repeated in Latino migrants in a Latino country. It is necessary to explore the influence of other variables in this relationship, since it seems that the best adaptive strategy, and therefore the cortisol response, will vary according to the socio-cultural context of the host country.

Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.

Benznidazole is the first-line drug used in treating Chagas disease, which is caused by the parasite Trypanosoma cruzi (T. cruzi). However, benznidazole has limited efficacy and several adverse reactions. Pentamidine is an antiprotozoal drug used in the treatment of leishmaniasis and African trypanosomiasis. In T. cruzi, pentamidine blocks the transport of putrescine, a precursor of trypanothione, which constitutes an essential molecule in the resistance of T. cruzi to benznidazole. In the present study, we describe the effect of the combination of benznidazole and pentamidine on isolated parasites, mammalian cells and in mice infected with T. cruzi. In isolated trypomastigotes, we performed a dose-matrix scheme of combinations, where pentamidine antagonized the effect of benznidazole, mainly at concentrations below the EC50 of pentamidine. In T. cruzi-infected mammalian cells, pentamidine reversed the effect of benznidazole (measured by qPCR). In comparison, in infected BALB/c mice, pentamidine failed to get synergy with benznidazole, measured on mice survival, parasitemia and amastigote nest quantification. To further explain the in vitro antagonism, we explored whether pentamidine affects intracellular trypanothione levels, however, pentamidine produced no change in trypanothione concentrations. Finally, the T. cruzi polyamine permease (TcPAT12) was overexpressed in epimastigotes, showing that pentamidine has the same trypanocidal effect, independently of transporter expression levels. These results suggest that, in spite of the high potency in the putrescine transport blockade, TcPAT12 permease is not the main target of pentamidine, and could explain the lack of synergism between pentamidine and benznidazole.

Novel Gallate Triphenylphosphonium Derivatives with Potent Antichagasic Activity.

disease is one of the most neglected tropical diseases in the world, affecting nearly 15 million people, primarily in Latin America. Only two drugs are used for the treatment of this disease, nifurtimox and benznidazole. These drugs have limited efficacy and frequently induce adverse effects, limiting their usefulness. Consequently, new drugs must be found. In this study, we demonstrated the in vitro trypanocidal effects of a series of four gallic acid derivatives characterized by a gallate group linked to a triphenylphosphonium (TPP(+)) moiety (a delocalized cation) via a hydrocarbon chain of 8, 10, 11, or 12 atoms (TPP(+)-C8, TPP(+)-C10, TPP(+)-C11, and TPP(+)-C12, respectively). We analyzed parasite viability in isolated parasites (by MTT reduction and flow cytometry) and infected mammalian cells using T. cruzi Y strain trypomastigotes. Among the four derivatives, TPP(+)-C10 and TPP(+)-C12 were the most potent in both models, with EC50 values (in isolated parasites) of 1.0 ± 0.6 and 1.0 ± 0.7 µM, respectively, and were significantly more potent than nifurtimox (EC50 = 4.1 ± 0.6 µM). At 1 µM, TPP(+)-C10 and TPP(+)-C12 induced markers of cell death, such as phosphatidylserine exposure and propidium iodide permeabilization. In addition, at 1 µM, TPP(+)-C10 and TPP(+)-C12 significantly decreased the number of intracellular amastigotes (TPP(+)-C10: 24.3%, TPP(+)-C12: 19.0% of control measurements, as measured by DAPI staining) and the parasite's DNA load (C10: 10%, C12: 13% of control measurements, as measured by qPCR). Based on the previous mode of action described for these compounds in cancer cells, we explored their mitochondrial effects in isolated trypomastigotes. TPP(+)-C10 and TPP(+)-C12 were the most potent compounds, significantly altering mitochondrial membrane potential at 1 µM (measured by JC-1 fluorescence) and inducing mitochondrial transition pore opening at 5 µM. Taken together, these results indicate that the TPP(+)-C10 and TPP(+)-C12 derivatives of gallic acid are promising trypanocidal agents with mitochondrial activity.